U.S. Stocks in Motion | Third-Quarter Innovative Drug Revenue Up 33% Year-over-Year, Teva Pharmaceutical (TEVA.US) Rises Over 4%

Zhito Finance APP has learned that on Tuesday, Teva Pharmaceutical (TEVA.US) rose more than 4% to $42.65, hitting a record high. In terms of news, Teva Pharmaceutical released its third-quarter 2026 financial report, with non-GAAP earnings per share of $0.86, beating market expectations by $0.14; revenue was $4.4 billion, down 2% year over year, beating market expectations by $170 million.